📈SEC Review of Bitwise XRP ETF Listing Proposal
The SEC has designated a longer review period for the proposed rule change to list and trade shares of the Bitwise XRP ETF under BZX Rule 14.11(e)(4). Following the initial filing, the SEC is allowing additional time to consider the implications before issuing an approval or disapproval order, reflecting the complexities of cryptocurrency regulation and trading practices.
Learn More📝IRS Notice on Information Collection for Tax Forms 4506 and 4506T-EZ
In accordance with the Paperwork Reduction Act of 1995, the IRS is inviting comments on the information collection request outlined in this notice.
Learn More🏥FDA Classifies Liver Iron Concentration Imaging Diagnostic
The Food and Drug Administration (FDA, the Agency, or we) is classifying the liver iron concentration imaging companion diagnostic for deferasirox into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the liver iron concentration imaging companion diagnostic for deferasirox. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More🏺Notice of Intended Repatriation by Pacific Grove Museum
In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the Pacific Grove Museum of Natural History (Pacific Grove Museum) intends to repatriate a certain cultural item that meets the definition of an object of cultural patrimony and that has a cultural affiliation with the Indian Tribes or Native Hawaiian organizations in this notice.
Learn More💊Public Meeting on Financial Transparency for Prescription Drug Fees
The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.
Learn More🚫DEA Revokes Registration for Physician Following License Suspension
The Drug Enforcement Administration has issued an Order to Show Cause for the revocation of Kenneth Pherson, D.O.'s registration, citing the suspension of his state medical license in Florida. This decision emphasizes the necessity for practitioners to maintain state authority to prescribe controlled substances, as federal compliance hinges on state licensure. The document details the procedural actions taken by the DEA and the implications of default by the registrant.
Learn More⚠️OSHA Extends Cadmium Rulemaking Comment Period
OSHA is extending the period for submitting comments by 60 days to allow stakeholders interested in the Notice of Proposed Rulemaking (NPRM) on Cadmium additional time to review the NPRM and collect information and data necessary for comment.
Learn More🏺Notice of Intended Repatriation from University of Michigan
In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the University of Michigan intends to repatriate certain cultural items that meet the definition of unassociated funerary objects that have a cultural affiliation with the Indian Tribes or Native Hawaiian organizations in this notice.
Learn More🏺Notice of Repatriation of Cultural Items in Tennessee
In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the Tennessee Department of Environment and Conservation, Division of Archaeology (TDEC-DOA) and the University of Tennessee, McClung Museum of Natural History & Culture (UTK) intend to repatriate certain cultural items that meet the definition of unassociated funerary objects and that have a cultural affiliation with the Indian Tribes or Native Hawaiian organizations in this notice.
Learn More💰HRSA Notice of $440,000 Supplemental Award for Early Childhood Health
HRSA is providing additional award funds of $440,000 in fiscal year (FY) 2025 to ZERO TO THREE National Center for Infant, Toddler, and Families, Inc., the current recipient of the Early Childhood Developmental Health Systems (ECDHS) Program cooperative agreement (HRSA-22-091), to support the continuation of existing activities relating to early childhood development health services.
Learn More